Briacell Therapeutics
BCTX
21 hedge funds and large institutions have $538K invested in Briacell Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
19% more capital invested
Capital invested by funds: $452K → $538K (+$86K)
5% more funds holding
Funds holding: 20 → 21 (+1)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vontobel Holding
Zurich,
Switzerland
|
+$59.9K |
| 2 |
HF
HRT Financial
New York
|
+$55.6K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$20.2K |
| 4 |
LPL Financial
San Diego,
California
|
+$14K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$12.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$131K |
| 2 |
Renaissance Technologies
New York
|
-$17.1K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$15.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$13.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.19K |
BCTX Hedge Fund Activity: Q3 2024 in Review
21 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q3 2024, worth a combined $538K — up 19% from $452K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BCTX positions and 5 closed out — a net gain of 1 holder — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Vontobel Holding, opening a new position worth an estimated $59.9K. The largest seller was Redmond Asset Management, exiting entirely with an estimated $131K sold.
- 21 institutional investors held Briacell Therapeutics (BCTX) as of Q3 2024, up from 20 in Q2 2024.
- Funds reported $538K of Briacell Therapeutics stock for Q3 2024, up 19% quarter-over-quarter.
- 6 funds opened new Briacell Therapeutics positions in Q3 2024 and 5 closed out, a net change of +1 holder.
- The largest Briacell Therapeutics buyer in Q3 2024 was Vontobel Holding, an estimated $59.9K added.
- The largest Briacell Therapeutics seller in Q3 2024 was Redmond Asset Management, an estimated $131K sold.
Based on aggregated 13F filings for Q3 2024.